Author: Julio Martinez-Clark

• What Makes a PMA Different From Other Approval Pathways
• The Core Components of a PMA Clinical Evidence Package
  • Investigational Device Exemption (IDE) Approval
  • Clinical Protocol and Study Design
  • Pre-Submission (Q-Sub) Meetings
  • Statistical Analysis Plan (SAP)
  • Clinical Study Report (CSR)
  • Device History and Bench Data
• Where Sponsors Build Weak Evidence Packages
• How Trial Location Affects Your Evidence Package
• Building the Evidence Package With a Single Accountable Team
• The Pre-PMA Submission Checklist
• What the FDA Reviews in the Clinical Section
• FAQs: PMA Clinical Trial Requirements
• Build the Evidence Package Before You Need It

A PMA clinical trial is one of the most demanding regulatory milestones a medical device company will face. Unlike the 510(k) pathway, which relies on substantial equivalence to a predicate, Premarket Approval requires you to generate original clinical evidence demonstrating that your device is safe and effective for its intended use. The FDA will not approve a Class III device on bench data and animal studies alone. You need a clinical evidence package, and it needs to be built correctly from the start.

This article covers what the FDA expects, how to structure that package, where most sponsors go wrong, and how your trial execution strategy affects the quality and timing of the data you ultimately submit.

---

What Makes a PMA Different From Other Approval Pathways

The PMA pathway applies to Class III devices: those that support or sustain human life, present a potential unreasonable risk of illness or injury, or lack a substantially equivalent predicate. Implantable cardiac devices, neurostimulators, and certain diagnostic systems are common examples.

Because no predicate exists, the FDA requires sponsors to prove safety and effectiveness through valid scientific evidence. That standard is defined in 21 CFR Part 860 and typically means well-controlled clinical investigations producing statistically valid results.

The 510(k) pathway can sometimes be cleared with retrospective data or literature reviews. The PMA pathway almost never can. You are building a prospective clinical record from scratch.

---

The Core Components of a PMA Clinical Evidence Package

The FDA expects the clinical section of a PMA submission to contain several interconnected elements. Missing or underpowered components are the most common trigger for Additional Information (AI) requests and major deficiencies.

Investigational Device Exemption (IDE) Approval

Before enrolling a single patient in a significant-risk device study, you need an approved IDE under 21 CFR Part 812. The IDE authorizes use of your device in human subjects during the investigation phase. For significant-risk devices, it is not optional.

Your IDE application must include the investigational plan (protocol), a risk analysis, device description, informed consent procedures, IRB approvals, and a monitoring plan. The FDA has 30 days to respond. If they do not disapprove it within that window, you may proceed.

The IDE is the foundation of your clinical evidence package. A weak protocol produces weak data. What you write at this stage directly determines whether the evidence you collect will hold up in the PMA submission.

Clinical Protocol and Study Design

The protocol is where most sponsors either set themselves up for success or create problems they will spend years correcting. The FDA expects a study design that:

• Defines a primary endpoint that maps directly to the device's intended use
• Specifies a statistically justified sample size with power calculations
• Identifies a control arm or objective performance criteria (OPC) where applicable
• Describes follow-up duration sufficient to capture the safety and effectiveness signals relevant to the indication
• Pre-specifies analysis populations (intent-to-treat, per-protocol) and statistical methods

Adaptive designs are increasingly accepted, but they require pre-specification of adaptation rules and FDA agreement before the trial begins. Do not adapt your protocol mid-study without prior FDA concurrence.

Pre-Submission (Q-Sub) Meetings

Before finalizing your protocol, request a Pre-Submission (Pre-Sub) meeting with the FDA under the Q-Submission program. This is one of the highest-leverage steps available to any PMA sponsor. A Pre-Sub gives you written FDA feedback on your proposed study design, endpoints, and statistical analysis plan before you commit to executing the trial.

Sponsors who skip the Pre-Sub and design protocols in isolation frequently discover at the PMA review stage that the FDA had different expectations about endpoint definitions, follow-up duration, or the adequacy of the control. That discovery, made after data collection is complete, is expensive and sometimes fatal to the program.

Use the Pre-Sub to confirm your primary endpoint, discuss the acceptability of your control strategy, and align on what "valid scientific evidence" means for your specific device and indication.

Statistical Analysis Plan (SAP)

The SAP must be finalized and locked before unblinding or completing enrollment. It specifies every analysis the FDA will review: primary and secondary endpoint analyses, subgroup analyses, handling of missing data, multiplicity adjustments, and interim analysis rules if applicable.

A SAP written after the fact, or one that does not match the protocol, is a major deficiency. The FDA's reviewers are statisticians. They will compare your SAP to your protocol and to your actual analysis. Discrepancies get flagged.

Clinical Study Report (CSR)

The CSR is the formal document presenting all clinical findings from your investigation. It follows ICH E3 structure and must include:

• Full protocol and amendments
• Patient disposition and demographics
• Primary and secondary endpoint results with confidence intervals
• Adverse event and serious adverse event summaries
• Subgroup analyses
• Individual patient data listings

The CSR is not a summary. It is a complete, auditable record of what happened in the trial. The FDA reviewer will read it alongside your raw data. Inconsistencies between the narrative and the data tables are a recurring source of deficiencies.

Device History and Bench Data

The clinical section does not stand alone. The FDA reviews it alongside your device description, bench testing, biocompatibility data (ISO 10993), sterilization validation, and software documentation where applicable. The clinical evidence package must be internally consistent with the device you tested. If your final design changed after IDE approval, document those changes and assess whether they affect the clinical data's applicability.

---

Where Sponsors Build Weak Evidence Packages

Several patterns consistently produce deficient PMA submissions.

Underpowered studies. Sample size calculations that assume unrealistically high effect sizes or low event rates result in studies that cannot demonstrate effectiveness even when the device performs well. The FDA will not accept a study that was never capable of answering the question it was designed to answer.

Endpoint drift. Changing the primary endpoint after data collection begins, even informally, is a serious problem. If your final CSR analyzes a different primary endpoint than the one in your IDE-approved protocol, the FDA will treat the original endpoint as primary and the new one as exploratory. Plan your endpoints carefully and hold to them.

Inadequate follow-up. For implantable or long-term-use devices, the FDA often expects data at 12, 24, or 36 months. Sponsors who design studies with six-month follow-up to save time frequently receive AI requests requiring additional data collection, extending the overall timeline by more than the time they tried to save.

Site qualification gaps. Sites that are not properly qualified, trained, or monitored produce data with integrity questions. The FDA can and does inspect clinical sites during PMA review. Data from sites with significant protocol deviations or monitoring deficiencies may be excluded from the analysis.

Missing or incomplete informed consent documentation. Every enrolled patient must have a properly documented informed consent process. Missing consent forms, or forms that do not reflect the approved protocol version, are a recurring finding in FDA inspections.

---

How Trial Location Affects Your Evidence Package

Where you run your PMA clinical trial has a direct effect on how quickly you can generate data and what it costs to generate it. These are not trivial considerations when your runway is finite and your board is watching the milestone calendar.

US-based trials for significant-risk devices face IRB review timelines of three to six months per site, site activation timelines that often stretch beyond a year for complex devices, and per-patient costs that can run well above $30,000 depending on the indication and site infrastructure.

Latin American markets operate differently. In Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are consistently observed in 30 to 90 days. That reflects actual observed performance across those markets, not a contractual guarantee from the health authorities. Patient populations in these countries are often treatment-naive for novel devices, which can improve enrollment rates and reduce the confounding effect of prior interventions on your primary endpoint.

The critical question for PMA purposes is whether data collected outside the US will be accepted by the FDA. The answer is yes, when the data is collected under an IDE and structured in accordance with 21 CFR 812.28, which governs the acceptance of foreign clinical study data. The study must be conducted under conditions comparable to US standards, using ICH-GCP-compliant protocols and ISO 14155 trial architecture. When those conditions are met, foreign clinical data supports both IDE and PMA submissions.

This is not a workaround. It is an established FDA framework that sponsors have used to accelerate timelines without compromising the quality of the evidence package.

---

Building the Evidence Package With a Single Accountable Team

The most common operational failure in PMA clinical programs is fragmentation. Sponsors use one vendor for regulatory strategy, a second for protocol development, a third for site management, and a fourth for data management. When the FDA asks a question about the relationship between a protocol amendment and a data collection change, no single person can answer it. The evidence package reflects the seams between vendors.

A structured approach that covers all workstreams under one accountable team produces a more coherent evidence package and a faster path through FDA review. Every component, from the Pre-Sub meeting through the final CSR, needs to be built by people who understand how each piece connects to the next.

bioaccess® operates the FIH-12 program on exactly this model: nine workstreams managed by a single team, from FDA Pre-Sub and IDE/IND pathway alignment through protocol development, site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package within a 12-month timeline. Trial execution runs across 19 Latin American and Caribbean markets through a network of 50-plus pre-qualified sites, with the final deliverable structured for the sponsor's next FDA regulatory step.

For PMA programs, that means the CSR and organized data room arrive ready for submission, not requiring reconstruction by a regulatory affairs team that was not present during the trial.

---

The Pre-PMA Submission Checklist

Before submitting your PMA, the clinical section should contain the following:

• Approved IDE and all amendments
• Final protocol with all versions documented
• Locked statistical analysis plan
• IRB approvals for all sites
• Informed consent forms for all enrolled patients
• Clinical study report following ICH E3 structure
• Adverse event narratives for all serious adverse events
• Individual patient data listings
• Site monitoring reports and audit trails
• Investigator qualifications and CVs
• Device accountability records

If any of these elements is missing or incomplete at submission, expect an AI request. AI requests add months to your review timeline. Getting the evidence package right before submission is faster than correcting it afterward.

---

What the FDA Reviews in the Clinical Section

The FDA's review of the clinical section focuses on several core questions:

1. Was the study designed to answer the right question for the intended use?
2. Was it conducted in accordance with the approved protocol and applicable regulations?
3. Does the primary endpoint analysis demonstrate a reasonable assurance of safety and effectiveness?
4. Are the adverse event data complete and accurately reported?
5. Do the benefits outweigh the risks for the intended patient population?

Reviewers are not looking for perfection. They are looking for scientific rigor, regulatory compliance, and honest reporting. A well-designed study showing modest benefit with a clear safety profile is more likely to succeed than an ambitious study with data integrity problems.

---

FAQs: PMA Clinical Trial Requirements

What is a PMA clinical trial and when is it required?
A PMA clinical trial is a clinical investigation conducted to generate the safety and effectiveness data required for FDA approval of a Class III medical device. It is required when a device cannot be cleared through the 510(k) pathway because no substantially equivalent predicate exists, or when the device presents a high risk to patients.

Do I need an IDE before starting a PMA clinical trial?
Yes. For significant-risk devices, an approved Investigational Device Exemption (IDE) under 21 CFR Part 812 is required before enrolling patients. The IDE application includes your protocol, risk analysis, device description, and IRB approvals. The FDA has 30 days to respond before you may proceed.

Can I use clinical data collected outside the United States in a PMA submission?
Yes. Foreign clinical data is accepted in PMA submissions when collected under an IDE and structured in accordance with 21 CFR 812.28. The study must be conducted under ICH-GCP-compliant conditions and meet the applicable FDA standards for the evidence type.

What is a Pre-Submission meeting and why does it matter for PMA programs?
A Pre-Submission (Pre-Sub or Q-Sub) meeting is a formal FDA feedback mechanism that allows sponsors to get written agency input on study design, endpoints, and statistical approaches before committing to a trial. For PMA programs, it is one of the most important steps you can take to reduce the risk of a major deficiency at the review stage.

How long does a PMA clinical trial typically take?
Timeline depends on the indication, study design, enrollment rate, and follow-up requirements. US-based trials for significant-risk devices commonly take 18 to 36 months from IDE approval to CSR completion. Trials executed in Latin American markets with faster regulatory approval timelines can compress the pre-enrollment phase significantly, though follow-up duration is determined by the protocol, not the geography.

What is the most common reason for a PMA clinical deficiency?
Underpowered study designs, endpoint drift, inadequate follow-up, and site data integrity issues are the most frequent sources of major deficiencies. Endpoint drift is the most preventable, and it is eliminated by finalizing your endpoints during the Pre-Sub process and locking your SAP before data collection begins.

How should the clinical study report be structured for a PMA submission?
The CSR should follow ICH E3 structure and include the full protocol and amendments, patient disposition, primary and secondary endpoint results with confidence intervals, adverse event summaries, subgroup analyses, and individual patient data listings. It must be internally consistent with the data tables and the approved protocol. Inconsistencies between the narrative and the data are a common source of AI requests.

---

Build the Evidence Package Before You Need It

The clinical evidence package for a PMA submission is not something you assemble at the end of a trial. It is built incrementally, starting with the Pre-Sub meeting and ending with a locked CSR and organized data room. Every decision made during protocol development, site selection, and data management either strengthens or weakens the package you will eventually hand to the FDA.

Sponsors who treat the evidence package as a documentation exercise discover its importance during review. Sponsors who treat it as the product of the trial build programs that move through FDA review with fewer deficiencies and shorter timelines.

If you are planning a PMA clinical trial and want to understand how trial execution in Latin America fits into your FDA evidence strategy, bioaccess® works with MedTech sponsors at exactly this stage of program planning.

---

WordPress category: Navigating Regulatory Landscapes in Latin America

• What Design Freeze Actually Means
• Why Design Freeze Is a Hard Dependency for Clinical Trials
• Design Freeze and the IDE Application
• The Verification and Validation Connection
• Design Freeze Timing and Your Clinical Trial Timeline
• What Happens When Design Freeze Is Delayed
• How Design Freeze Interacts With Non-U.S. Regulatory Submissions
• Practical Steps to Prepare for Design Freeze
• Design Freeze as a Clinical Readiness Gate
• FAQs
• Conclusion

Design freeze is one of the most consequential decisions in medical device development — and it sits directly on the critical path to your first-in-human trial. Get it right and your clinical timeline stays intact. Get it wrong and you're looking at protocol amendments, re-verification cycles, and months of delay before a single patient is enrolled.

This article explains what design freeze means, why it matters for regulatory submissions, and how the timing of that decision shapes everything downstream — including your IDE application, site activation, and the overall clock on your FIH program.

---

What Design Freeze Actually Means

Design freeze is the formal point at which a medical device's design is locked. From that point forward, no changes are made to specifications, materials, software, or manufacturing processes without going through a controlled change management procedure.

Under FDA 21 CFR Part 820 and ISO 13485, design freeze is embedded within the broader design control process. It typically follows design verification and validation (V&V) and precedes transfer to manufacturing. The device you freeze is the device you test in humans. That's the core logic.

One clarification worth making: design freeze is not the same as design lock or design transfer, though early-stage teams often use all three interchangeably. Design lock tends to be informal — something used during iterative development. Design freeze is the formal, documented event. Design transfer is what comes after, when the device moves into a manufacturing environment for clinical unit production.

---

Why Design Freeze Is a Hard Dependency for Clinical Trials

Your clinical trial protocol is written around a specific device. The device description in your IDE application, the Instructions for Use, the risk analysis, the labeling — all of it references a defined configuration. If the device changes after the protocol is finalized, you have a mismatch.

That mismatch creates real downstream problems:

• Protocol amendments require ethics committee and regulatory authority re-approval, adding weeks or months to your timeline
• IDE supplements may be required if the change is significant enough to affect safety or effectiveness
• Site training has to be repeated if the device interface or operating procedure changes
• Informed consent documents may need revision if the risk profile shifts

None of these are fatal on their own. Compounded, they can push a 12-month FIH program into 18 or 24 months. For a startup with a board deadline tied to first human data, that's not an abstract risk.

The practical rule: design freeze should be completed before your IDE submission, not alongside it. Many early-stage teams treat IDE filing as a parallel track to final design iterations. That approach almost always produces re-work.

---

Design Freeze and the IDE Application

The Investigational Device Exemption (IDE) application under 21 CFR Part 812 requires a device description specific enough for FDA to evaluate safety. If your device is still changing, you can't write a stable device description — and FDA reviewers will identify inconsistencies between the device description, the risk analysis, and the testing reports. Questions will follow.

A Pre-Submission meeting (Pre-Sub) with FDA — which bioaccess® builds into the FIH-12 program from day one — is the right place to confirm what level of design finality FDA expects before you file. For most non-significant risk devices, FDA will want to see that V&V testing was conducted on the configuration that will actually be used in the trial. For significant risk devices, the bar is higher.

The Pre-Sub also gives you the opportunity to align on your clinical protocol, primary endpoints, and statistical plan before you've committed to a frozen design. That sequencing matters: your protocol should inform your design requirements, not the other way around.

---

The Verification and Validation Connection

Design freeze can't happen in isolation from V&V. Verification asks whether the device meets its design specifications. Validation asks whether those specifications meet user needs and intended uses. Both must be completed on the device as it will be manufactured for the trial.

This is where teams consistently run into trouble. Bench testing is often conducted on prototypes that differ from the final clinical unit. If the clinical unit is manufactured differently — different materials, different tolerances, different assembly process — the V&V data may not be representative. FDA and ethics committees reviewing your submission will ask whether testing was conducted on the same configuration that will be used in patients.

The answer needs to be yes. That means your manufacturing process for clinical units must be defined and controlled before you freeze. If you're using a contract manufacturer, their process needs to be qualified. If you're producing units in-house, your production records need to be in place.

This is not a small lift for an early-stage team. It's one of the main reasons the window between design freeze and IDE submission is often longer than founders expect.

---

Design Freeze Timing and Your Clinical Trial Timeline

Here's a practical timeline structure showing how design freeze fits into the broader FIH sequence:

12 to 18 months before first patient enrolled:

• Complete design history file (DHF) through final design inputs and outputs
• Conduct design V&V on clinical-representative units
• Complete risk management file per ISO 14971

9 to 12 months before first patient enrolled:

• Achieve formal design freeze
• Finalize device description for IDE application
• Begin protocol development and Pre-Sub preparation

6 to 9 months before first patient enrolled:

• Submit IDE application (or prepare for ethics-only submission in applicable jurisdictions)
• Begin site qualification and ethics submissions in parallel

3 to 6 months before first patient enrolled:

• Receive IDE approval or ethics committee approvals
• Complete site activation and investigator training
• Begin enrollment

Design freeze sits near the top of this sequence. It's a precondition, not a concurrent activity.

For sponsors running trials in Panama, El Salvador, Chile, or the Dominican Republic through the FIH-12 program, ethics and regulatory approvals in those jurisdictions are observed in 30 to 90 days. That compressed approval window is a structural feature of those regulatory systems — not a best-case scenario. But it only helps you if your device is frozen and your submission is ready to file. A 30-day approval window doesn't recover time lost to late design changes.

---

What Happens When Design Freeze Is Delayed

Late design freeze is one of the most common sources of FIH timeline slippage, and it compounds in ways that aren't obvious at the outset.

Consider a team that delays freeze by three months to incorporate feedback from a usability study. Those three months push the IDE submission. The IDE submission pushes ethics committee filing. Ethics committee filing pushes site activation. Site activation pushes enrollment. By the time the delay works through the system, the program is six to nine months behind.

This isn't hypothetical. It's the standard pattern when design freeze is treated as a development milestone rather than a clinical trial dependency.

Post-freeze changes carry their own risk. If a significant change is required after freeze — a material substitution, a software update that affects safety, a dimensional change that shifts the risk profile — you need a formal design change process. That includes impact assessment, updated V&V testing, and potentially a protocol amendment and regulatory re-submission. Even minor changes typically add four to eight weeks when they touch regulatory submissions.

---

How Design Freeze Interacts With Non-U.S. Regulatory Submissions

If your FIH trial is running outside the United States, design freeze still anchors the submission. Ethics committees in Panama (MINSA/CNBI), Chile (ISP/MINSAL), and El Salvador (SRS/CNEIS) review the device description as part of their safety evaluation. They want to see the same thing FDA wants: a defined, tested device that matches the protocol.

One practical difference in LatAm submissions is that some jurisdictions accept a device description supported by bench testing data without requiring a full IDE. The evidentiary bar for ethics approval isn't identical to the FDA bar. But the underlying requirement — that the device is defined and stable — is the same across all of them.

Under FDA 21 CFR 812.28, data collected in foreign clinical investigations can support U.S. IDE and IND submissions when the trial is conducted under comparable ethical and scientific standards. That means the device used in a Panama or Chile FIH trial needs to be the same device described in the eventual U.S. submission. Design freeze is the mechanism that ensures that consistency.

---

Practical Steps to Prepare for Design Freeze

If you're planning a FIH trial and haven't yet frozen your design, here's what needs to be in place before you do:

Design history file (DHF) completeness. All design inputs, outputs, reviews, verification, and validation records should be current and traceable. Gaps in the DHF will surface during FDA review and ethics committee submission.

Risk management file. Your risk analysis per ISO 14971 should reflect the final device configuration. Post-freeze changes that affect the risk profile require the file to be updated.

Clinical-representative units. The units used in V&V testing should be manufactured using the same process, materials, and controls as the units that will be used in the trial. Document this explicitly.

Manufacturing controls. Whether you're using a contract manufacturer or producing in-house, your production process should be defined, controlled, and capable of producing consistent units. Clinical unit manufacturing is not prototype manufacturing.

Labeling draft. Your Instructions for Use and device labeling should be drafted before freeze. Labeling is part of the device definition, and post-freeze labeling changes can require re-approval.

Change control procedure. Changes happen even after freeze. Having a formal change control procedure in place before you freeze means you can handle them systematically rather than reactively.

---

Design Freeze as a Clinical Readiness Gate

The most useful reframe for early-stage teams is to treat design freeze as a clinical readiness gate, not just a development milestone. The question isn't "is the device good enough to freeze?" It's "is the device defined well enough to submit to FDA and ethics committees, train investigators, and enroll patients?"

That framing changes how you prioritize the work leading up to freeze. It pulls clinical operations, regulatory affairs, and quality into the design process earlier, rather than treating them as downstream consumers of whatever development produces.

For teams working toward a first-in-human trial in 12 to 24 months, that earlier integration is what keeps the timeline intact. The bioaccess® FIH-12 program is structured around exactly this kind of parallel-track coordination — nine workstreams running concurrently, with FDA Pre-Sub alignment and protocol development happening alongside design finalization rather than after it.

---

FAQs

What is design freeze in medical device development?
Design freeze is the formal, documented point at which a medical device's design is locked. No changes are made to specifications, materials, software, or manufacturing processes without a controlled change management procedure. It follows design verification and validation and precedes clinical unit manufacturing.

Does design freeze have to happen before an IDE submission?
Yes, in practice. The IDE application requires a stable device description, and FDA evaluates safety based on the device as it will be used in the trial. If the device is still changing, the device description will be inconsistent with the testing data — which typically generates FDA questions and delays.

What happens if you need to change the device after design freeze?
Post-freeze changes require a formal design change process: impact assessment, updated V&V testing if the change affects safety or performance, and potentially a protocol amendment and regulatory re-submission. Depending on the magnitude of the change, expect weeks to months added to the clinical timeline.

Is design freeze required for trials outside the United States?
The formal requirement varies by jurisdiction, but the underlying logic is consistent. Ethics committees in Panama, Chile, El Salvador, and the Dominican Republic review the device description as part of their safety evaluation. The device needs to be defined and stable regardless of where the trial runs.

How does design freeze affect the timeline for a first-in-human trial?
Design freeze is a hard upstream dependency. Delays in freeze push IDE submission, which pushes ethics committee filing, which pushes site activation and enrollment. A three-month delay in freeze can translate to six to nine months of total timeline slippage when compounded through the sequence.

What documents need to be in place before design freeze?
At minimum: a complete design history file (DHF), a risk management file per ISO 14971, V&V records conducted on clinical-representative units, manufacturing controls documentation, a labeling draft, and a formal change control procedure.

Can data from a LatAm FIH trial support a U.S. IDE submission if the device was frozen before the trial?
Yes. Under FDA 21 CFR 812.28, data from foreign clinical investigations conducted under comparable ethical and scientific standards can support U.S. IDE submissions. The device used in the LatAm trial must be the same device described in the U.S. submission — which is exactly what design freeze ensures.

---

Conclusion

Design freeze is not a bureaucratic checkpoint. It's the moment your device becomes a clinical asset rather than a development project. Everything that follows in your FIH program — protocol development, IDE submission, ethics approvals, site activation, enrollment — depends on that device being defined, tested, and stable.

Teams that hit their FIH milestones on schedule treat design freeze as a clinical readiness gate and build their development timeline backward from it. Teams that miss those milestones usually delayed freeze while running parallel development tracks that eventually collided.

If you're 12 to 24 months from first human data and working through what your FIH timeline should look like, bioaccess® works with device and biopharma sponsors to structure that sequence from design freeze through a submission-ready evidence package.

• Why Latin America Works for Radiopharmaceutical Development
• Regulatory Pathways by Jurisdiction
  • Panama: MINSA and CNBI
  • Chile: ISP and MINSAL
  • El Salvador: SRS and CNEIS
  • Dominican Republic
• Site Requirements for Radiopharmaceutical Trials
  • Radiopharmacy and Isotope Handling
  • Imaging Infrastructure
  • Radiation Safety and Regulatory Compliance
• Building a Submission-Ready Evidence Package
  • Protocol Design Considerations
  • Data Management and Audit Readiness
  • FDA Bridgeability
• Working with a CRO That Knows the Terrain
• Practical Steps Before You Commit to a Jurisdiction
• FAQs
• Start with the Right Infrastructure

Radiopharmaceutical development has moved fast. Lutetium-177 DOTATATE reshaped the neuroendocrine tumor space, Actinium-225 programs are advancing across multiple oncology indications, and Gallium-68 diagnostics have become standard of care in several markets. If you are running a radiopharmaceutical program today, the question is no longer whether to pursue early human data — it is where to pursue it without burning through runway while a U.S. or EU regulatory clock ticks down.

Latin America has become a serious answer to that question. Ethics and regulatory approvals in Panama, El Salvador, Chile, and the Dominican Republic are observed in 30 to 90 days, compared to 6 to 12 months at equivalent stages in the U.S. or EU. For a seed-to-Series-B sponsor with 18 months of runway and a board milestone tied to first human data, that gap is the difference between making the next funding round and missing it.

This article covers what you need to know before running a radiopharmaceutical clinical trial in Latin America: the regulatory pathways by jurisdiction, the site infrastructure requirements specific to radionuclide work, and the practical steps for building a submission-ready evidence package that holds up at FDA.

---

Why Latin America Works for Radiopharmaceutical Development

The appeal goes beyond speed. Latin American clinical populations are diagnostically naive to many novel radiolabeled compounds, which reduces confounding from prior treatment exposure. Patient enrollment rates at experienced oncology centers in the region tend to outpace U.S. sites for the same indications. The cost structure is also meaningfully different: per-patient costs in Panama run between $12,000 and $22,000 — a fraction of comparable U.S. trial costs.

The regulatory data generated in these markets is not a workaround. Under FDA 21 CFR 812.28, foreign clinical data collected under ICH-GCP and ISO 14155 standards can be accepted in IDE and IND submissions when the evidence package is structured correctly. A first-in-human dataset completed in Panama or Chile can feed directly into your U.S. regulatory strategy without running a parallel domestic trial first.

For radiopharmaceutical programs specifically, the combination of fast regulatory entry, experienced nuclear medicine infrastructure, and FDA-bridgeable data collection makes Latin America a practical first stop before a U.S. pivotal study.

---

Regulatory Pathways by Jurisdiction

Radiopharmaceuticals occupy a hybrid regulatory category across most Latin American markets — typically classified as either radiopharmaceutical drugs or radioactive medical devices, with the pathway depending on whether the compound is primarily diagnostic or therapeutic. Getting the classification right upfront saves months of back-and-forth with the relevant authority.

Panama: MINSA and CNBI

Panama's Ministry of Health (MINSA) and the National Bioethics Committee (CNBI) jointly govern clinical trial approvals. Radiopharmaceuticals fall under MINSA's pharmaceutical directorate, with CNBI providing parallel ethics review. The 30-to-90-day approval window reflects a well-established process for both drug and device sponsors.

Nuclear medicine infrastructure is concentrated in Panama City, where several sites have cyclotrons or radiopharmacy capabilities for Ga-68 production and established protocols for Lu-177 administration. Ac-225 programs require additional radiation safety documentation, but the regulatory framework accommodates them. Panama is also the most cost-transparent market in the region for trial budgeting, which is why per-patient benchmarks are most reliably cited there.

Chile: ISP and MINSAL

Chile's Institute of Public Health (ISP) and Ministry of Health (MINSAL) share jurisdiction over clinical trial approvals. Chile has one of the most developed nuclear medicine networks in South America, with PET/CT infrastructure at major academic medical centers in Santiago and several regional cities.

The ISP pathway for radiopharmaceuticals requires a dossier covering the investigational product's radiochemical characterization, dosimetry data, and radiation safety protocols. For Ga-68 diagnostics, ISP review tends to move faster because the compound class is well understood. For novel therapeutic isotopes like Ac-225, expect additional technical questions and plan for a documentation-heavy submission. Approval timelines are consistent with Panama's 30-to-90-day range, though novel radiopharmaceuticals can run toward the longer end.

El Salvador: SRS and CNEIS

El Salvador's Regulatory Health System (SRS) and the National Committee for Ethics in Health Research (CNEIS) manage clinical trial oversight. The market is smaller than Panama or Chile, but it has been used effectively for early feasibility studies where enrollment targets are modest. For radiopharmaceutical trials, the site network is more limited, and sponsors should confirm site-level radiation safety infrastructure before committing to El Salvador as a primary execution market for radionuclide therapeutics.

Dominican Republic

The Dominican Republic offers approval timelines comparable to Panama and El Salvador. For radiopharmaceutical development, it functions better as a secondary enrollment site than a primary execution market, given the current state of nuclear medicine infrastructure relative to Panama and Chile.

---

Site Requirements for Radiopharmaceutical Trials

Running a Lu-177, Ac-225, or Ga-68 trial is not the same as running a standard oncology drug or device study. The site infrastructure requirements are specific, and failing to qualify them upfront is one of the most common reasons radiopharmaceutical programs slip their timelines.

Radiopharmacy and Isotope Handling

Ga-68 diagnostic programs require either an on-site cyclotron or a reliable supply chain from a regional radiopharmacy. With a 68-minute half-life, the logistics of production-to-administration are tightly constrained. Sites in Panama City and Santiago have demonstrated this capability, but the specific supply arrangement for your compound needs to be confirmed before site selection is finalized.

Lu-177 programs require a licensed radiopharmacy capable of receiving, labeling, and dispensing the therapeutic compound. The roughly 6.6-day half-life provides more logistical flexibility than Ga-68, but the radiation safety infrastructure requirements are higher — dedicated hot labs, appropriate waste disposal protocols, and staff trained in therapeutic radiopharmaceutical administration are all necessary.

Ac-225 is the most demanding of the three. With a half-life of approximately 10 days and daughter isotopes requiring careful containment, Ac-225 programs need sites with advanced radiation safety programs, dosimetry expertise, and direct experience with alpha-emitting therapeutics. This narrows the qualified site pool in Latin America, but qualified sites do exist within bioaccess®'s 50-plus pre-qualified network, which was built specifically for this work.

Imaging Infrastructure

Most radiopharmaceutical trials require PET/CT or SPECT/CT imaging at defined protocol timepoints. Site qualification must confirm scanner availability, calibration standards, and image acquisition protocols that match your study's requirements. For multi-site trials, image standardization across sites is a protocol design consideration — not just an operations issue.

Chile's academic centers offer modern PET/CT infrastructure with experience in quantitative imaging for research protocols. Panama's imaging infrastructure is concentrated at a smaller number of sites, which affects how many sites can realistically be activated for a radiopharmaceutical study.

Radiation Safety and Regulatory Compliance

Every site running a radiopharmaceutical trial needs a radiation safety officer, documented radiation protection protocols, and a license to handle the specific isotopes in the protocol. In Latin America, radiation safety oversight typically falls under the national nuclear energy authority in addition to the health ministry — CCHEN in Chile, and the National Secretariat of Energy in Panama.

Site qualification should include a review of the site's current radiation safety license, the scope of isotopes covered, and prior experience with the specific compound class. This step cannot be skipped, and it should happen before ethics submission, not after.

---

Building a Submission-Ready Evidence Package

The goal of a Latin American radiopharmaceutical trial is not just to generate human data. It is to generate data your FDA regulatory team can use in an IND or IDE submission without repeating the study domestically.

That requires three things from the start: a protocol designed to ICH-GCP and ISO 14155 standards, a data management system that produces audit-ready records, and a regulatory strategy that keeps the U.S. pathway in view throughout execution.

Protocol Design Considerations

Radiopharmaceutical first-in-human protocols need to address dosimetry, safety monitoring, and imaging endpoints in ways that satisfy both the local regulatory authority and FDA's expectations for foreign clinical data. Dosimetry assessments are typically required at multiple timepoints, with the protocol specifying how that data will be collected, analyzed, and reported.

Stopping rules and dose escalation criteria need to be defined with the same rigor required for a U.S. IND submission. Local ethics committees in Panama and Chile are experienced with oncology protocols and will scrutinize these sections carefully.

Data Management and Audit Readiness

Electronic data capture systems used in Latin American radiopharmaceutical trials must meet FDA 21 CFR Part 11 requirements for electronic records — a non-negotiable condition for data destined for a U.S. submission. Data management plans should specify how imaging data, dosimetry calculations, adverse event records, and laboratory results will be captured, stored, and made available for FDA review.

FDA Bridgeability

Under 21 CFR 812.28, FDA can accept data from foreign clinical investigations conducted under conditions comparable to U.S. standards. For radiopharmaceutical programs, the evidence package needs to document the site's radiation safety infrastructure, principal investigator qualifications, GCP compliance of trial conduct, and the integrity of the data chain from collection to submission.

Structuring for FDA bridgeability is not something you retrofit at the end of the trial. It has to be designed into the program from the protocol development stage.

---

Working with a CRO That Knows the Terrain

Radiopharmaceutical development in Latin America is not a standard clinical operations project. The combination of isotope-specific site requirements, dual-authority regulatory pathways, and FDA bridgeability standards demands a team that has run these programs before.

bioaccess® operates dedicated radiopharmaceutical trial capability covering Lu-177, Ac-225, and Ga-68 programs across its 19-country Latin American and Caribbean footprint. The FIH-12 program covers all nine workstreams — from FDA Pre-Sub and IND/IDE pathway alignment through site activation, patient enrollment, data management, and delivery of a submission-ready evidence package — with a 12-month timeline guarantee on the program structure.

The 50-plus pre-qualified site network includes locations with confirmed nuclear medicine and radiopharmacy infrastructure. Site qualification for radiopharmaceutical trials goes beyond standard GCP readiness to include radiation safety licensing, isotope handling capability, and imaging protocol standardization.

Intake is capped at eight new programs per quarter — a reflection of the operational depth these programs require, not a volume model.

---

Practical Steps Before You Commit to a Jurisdiction

Before selecting a primary execution market for your radiopharmaceutical trial, work through these questions:

Isotope logistics. What is the half-life of your compound, and what does that require from the site's radiopharmacy? Can the supply chain support your dosing schedule across the sites you plan to activate?

Site qualification scope. Does the site hold a radiation safety license that covers your specific isotope? Has the principal investigator administered this compound class before, or would this be their first experience with it?

Regulatory classification. How will the local authority classify your compound? Diagnostic and therapeutic radiopharmaceuticals follow different pathways in most jurisdictions, and getting the classification wrong at submission adds weeks to the review.

FDA strategy alignment. Is your protocol designed to produce data FDA will accept under 21 CFR 812.28? Has your regulatory counsel reviewed it against FDA's expectations for foreign clinical data before you submit to the local authority?

Timeline against runway. If approvals run toward the longer end of the 30-to-90-day observed range, does your program timeline still hold against your next funding milestone?

These are not questions you answer once and move on. They should be revisited at each stage of program design, because the answers affect site selection, protocol design, and regulatory submission strategy simultaneously.

---

FAQs

What regulatory authorities govern radiopharmaceutical clinical trials in Latin America?
It depends on the jurisdiction. Panama uses MINSA and CNBI. Chile uses ISP and MINSAL. El Salvador uses SRS and CNEIS. Beyond health ministry oversight, radiation safety for nuclear compounds typically falls under a separate national nuclear authority — CCHEN in Chile, the National Secretariat of Energy in Panama. Sponsors need to satisfy both sets of requirements before a trial can begin.

Can data from a Latin American radiopharmaceutical trial be used in a U.S. IND submission?
Yes, when the trial is conducted under ICH-GCP and ISO 14155 standards and the evidence package is structured per FDA 21 CFR 812.28. The data is not automatically accepted — it must be presented in a format that documents site qualifications, GCP compliance, data integrity, and the comparability of trial conditions to U.S. standards. Structuring for FDA bridgeability needs to happen at the protocol design stage, not after data collection is complete.

Which Latin American markets have the strongest nuclear medicine infrastructure for radiopharmaceutical trials?
Panama and Chile are the most developed for radiopharmaceutical trial execution. Chile has multiple academic centers with PET/CT infrastructure and experience in quantitative imaging research. Panama has established radiopharmacy capabilities for Ga-68 and Lu-177 programs in Panama City. Ac-225 programs require more selective site qualification in any market due to alpha-emitter handling requirements.

How long does regulatory approval take for a radiopharmaceutical trial in Panama or Chile?
Ethics and regulatory approvals in both markets are observed in 30 to 90 days. These are observed outcomes based on completed submissions, not a contractual guarantee from the health authorities. Novel radiopharmaceuticals — particularly Ac-225 programs — may prompt additional technical questions that push review toward the longer end of that range.

What site infrastructure is required specifically for Lu-177 therapeutic trials?
Sites need a licensed radiopharmacy capable of receiving, labeling, and dispensing Lu-177, along with dedicated hot lab space, radioactive waste disposal systems, and staff trained in therapeutic radiopharmaceutical administration. Dosimetry expertise and SPECT/CT imaging capability are also required for most Lu-177 protocols.

What makes Ac-225 trials more complex than Lu-177 or Ga-68 programs?
Ac-225 is an alpha emitter with daughter isotopes that require careful containment and monitoring. Radiation safety infrastructure requirements are higher than for Lu-177 or Ga-68, and fewer sites have the experience and licensing to handle it. Site qualification for an Ac-225 program needs to include a detailed review of the site's radiation protection program, dosimetry capabilities, and prior experience with alpha-emitting compounds.

How does a CRO's role differ in a radiopharmaceutical trial compared to a standard device or drug study?
A CRO running a radiopharmaceutical trial needs to manage isotope-specific site qualification, dual-authority regulatory submissions covering both health and radiation safety, imaging protocol standardization across sites, and dosimetry data management — on top of standard GCP-compliant trial operations. The operational complexity is higher, and the consequences of site qualification gaps are more severe because isotope logistics cannot be improvised mid-study.

---

Start with the Right Infrastructure

Radiopharmaceutical development in Latin America is achievable, and the regulatory speed advantage is real. But it requires more upfront site qualification work, more specific regulatory strategy, and more careful protocol design than a standard early feasibility study.

If you are 12 to 24 months from needing first human data for a Lu-177, Ac-225, or Ga-68 program, the time to map the pathway is now — not after your IND is filed. Visit bioaccessla.com to get a preliminary country route and timeline estimate for your program.

---

WordPress Category: Navigating Regulatory Landscapes in Latin America